Second Quarter 2023 Earnings

revvity

August 1, 2023

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Transformation	Performance
Launched novel “Pin-Point” base editing platform and technology by signing initial license agreement with AstraZeneca	Global launch of the company as Revvity, Inc. Stock ticker changed to “RVTY” on May 16th.	Delivered solid 2Q Non-COVID organic growth and adjusted EPS at the upper-end of expectations. Adjusting outlook to reflect challenging macro environment

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

Q223 Revenue Highlights

Segments

Diagnostics Life Sciences



Geographic

AMERICAS APAC EU



Product Mix

RECURRING NON-RECURRING



Revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2Q23 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	NON-GAAP FREE CASH FLOW
$709M	**28.8%**	**$1.21**	**$(61)M**
⬇ -21% y/y	⬇ -1,080bps y/y	⬇ -39% y/y	⬇ -179% y/y
Organic: -20% | M&A: 0% | FX: 0%	Adj. Gross Margin: 62.4% | -530bps y/y	Adj. Tax Rate: 22.6%	Includes $127M of AES related outflows
Non-COVID: +6% organic growth		Adj. Net Interest & Other: $8M	
COVID: De minimis vs. $222M in 2Q'22			

Life Sciences

Product



REVENUE	AJUSTED OP MARGINS
+3% Organic Growth	38.0%
Reported: 3% | M&A: 0% | FX: 0%	-200bps y/y

- -LSD growth from Pharma/Biotech, +DD growth from Academic/Gov't
- +DD reagents organic growth
- Software in line with expectations due to timing of multi-year renewals

Diagnostics

End Market



REVENUE	
-34%	Organic Growth
Reported: -34% | M&A: 0% | FX: -1%	
Non-COVID Organic Growth: 8%	

AJUSTED OP MARGINS
22.9%
-2,012 bps y/y

- +DD ImmunoDx ex. China, China ImmunoDx >+30%
- +LSD Non-COVID organic growth in Applied Genomics consumables offset by –DD decline in instruments
- +DD Neonatal performance offset by Revvity Omics order timing

Revenue and revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2023 Financial Guidance

ADJ. REVENUE	**$2.80B - 2.85B**
	-15% to –14% reported
	Organic: -15% to -14%
	Non-COVID Organic: +4% to +6%
	FX: 0%, M&A: 0%
ADJUSTED OP. MARGIN	**~29%**
ADJUSTED EPS	**$4.70 - $4.90**
	Adj. Net interest expense, other: $63M
	Adjusted tax rate: 21%
	Average diluted share count: 125.0M



Revvity.com